BR9706824B8 - Suspensão aquosa de ésteres de ácido graxo de 9-hidróxi risperidona. - Google Patents

Suspensão aquosa de ésteres de ácido graxo de 9-hidróxi risperidona.

Info

Publication number
BR9706824B8
BR9706824B8 BRPI9706824-1B8A BR9706824A BR9706824B8 BR 9706824 B8 BR9706824 B8 BR 9706824B8 BR 9706824 A BR9706824 A BR 9706824A BR 9706824 B8 BR9706824 B8 BR 9706824B8
Authority
BR
Brazil
Prior art keywords
risperidone
fatty acid
acid esters
aqueous suspension
hydroxy fatty
Prior art date
Application number
BRPI9706824-1B8A
Other languages
English (en)
Other versions
BR9706824A (pt
Inventor
Marc Karel Jozef Francois
Roger Carolus Augusta Embrechts
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9706824(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9706824A publication Critical patent/BR9706824A/pt
Publication of BR9706824B8 publication Critical patent/BR9706824B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BRPI9706824-1B8A 1996-05-20 1997-05-12 Suspensão aquosa de ésteres de ácido graxo de 9-hidróxi risperidona. BR9706824B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
BR9706824A BR9706824A (pt) 1999-03-23
BR9706824B8 true BR9706824B8 (pt) 2015-02-18

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9706824-1B8A BR9706824B8 (pt) 1996-05-20 1997-05-12 Suspensão aquosa de ésteres de ácido graxo de 9-hidróxi risperidona.

Country Status (38)

Country Link
US (1) US6077843A (pt)
EP (1) EP0904081B1 (pt)
JP (1) JP3274687B2 (pt)
KR (1) KR100358373B1 (pt)
CN (1) CN1093762C (pt)
AR (1) AR007194A1 (pt)
AT (1) ATE208619T1 (pt)
AU (1) AU715572B2 (pt)
BG (1) BG62684B1 (pt)
BR (1) BR9706824B8 (pt)
CA (1) CA2236691C (pt)
CY (2) CY2270B1 (pt)
CZ (1) CZ291284B6 (pt)
DE (2) DE69708284T2 (pt)
DK (1) DK0904081T3 (pt)
EA (1) EA000536B1 (pt)
EE (1) EE03594B1 (pt)
ES (1) ES2167745T3 (pt)
FR (1) FR11C0035I2 (pt)
HK (1) HK1017852A1 (pt)
HR (1) HRP970276B1 (pt)
HU (2) HU224025B1 (pt)
ID (1) ID16927A (pt)
IL (1) IL124551A (pt)
LU (1) LU91842I2 (pt)
MX (1) MX9804816A (pt)
MY (1) MY126302A (pt)
NO (2) NO315931B1 (pt)
NZ (1) NZ330369A (pt)
PL (1) PL188309B1 (pt)
PT (1) PT904081E (pt)
SI (1) SI0904081T1 (pt)
SK (1) SK284013B6 (pt)
TR (1) TR199800923T2 (pt)
TW (1) TW487572B (pt)
UA (1) UA61898C2 (pt)
WO (1) WO1997044039A1 (pt)
ZA (1) ZA974331B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE265846T1 (de) * 1998-02-25 2004-05-15 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
US6667060B1 (en) 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
MXPA03001337A (es) * 2000-08-14 2005-06-30 Teva Pharma Preparacion de risperidona.
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
PT1539115E (pt) * 2002-07-29 2008-01-14 Alza Corp Métodos e formas de dosagem para libertação controlada de paliperidona
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
WO2005070332A1 (en) * 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
US8314110B2 (en) * 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
ES2868353T3 (es) 2007-12-19 2021-10-21 Janssen Pharmaceutica Nv Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
KR20120116401A (ko) 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2683717T3 (pl) 2011-05-31 2016-11-30 Wytwarzanie 3-[2-[4-((6-fluoro-1,2-benzoizoksazol-3-ilo)-1-piperydynylo)-6,7,8,9-tetrahydro-9- hydroksy-2-metylo-4H-pirydo[1,2-a]pirymidyn-4-onu (paliperydonu) i palmitynianu paliperydonu
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2802299T3 (es) 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US11439647B2 (en) 2020-11-30 2022-09-13 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
FI4025188T3 (fi) 2020-11-30 2024-02-21 Janssen Pharmaceutica Nv Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
JP2023552149A (ja) 2020-11-30 2023-12-14 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
WO2022112367A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
KR20240049580A (ko) 2021-08-20 2024-04-16 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
DE69611783T2 (de) * 1995-06-06 2001-09-20 Aventis Pharma Inc Benzisoxazol- und indazol- derivate als antipsychotika
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
MY126302A (en) 2006-09-29
FR11C0035I1 (pt) 2011-07-10
US6077843A (en) 2000-06-20
AU2955997A (en) 1997-12-09
NZ330369A (en) 2000-04-28
AR007194A1 (es) 1999-10-13
NO315931B1 (no) 2003-11-17
HRP970276B1 (en) 2002-04-30
HRP970276A2 (en) 1998-04-30
EA000536B1 (ru) 1999-10-28
CY2011011I1 (el) 2016-12-14
ZA974331B (en) 1998-11-19
ATE208619T1 (de) 2001-11-15
SI0904081T1 (en) 2002-04-30
LU91842I2 (fr) 2011-09-20
FR11C0035I2 (fr) 2013-08-16
MX9804816A (es) 1998-10-31
TW487572B (en) 2002-05-21
BR9706824A (pt) 1999-03-23
WO1997044039A1 (en) 1997-11-27
JP3274687B2 (ja) 2002-04-15
BG62684B1 (bg) 2000-05-31
DE122011100027I1 (de) 2011-11-17
SK284013B6 (sk) 2004-08-03
EE9800136A (et) 1998-10-15
EA199800531A1 (ru) 1998-12-24
DE69708284D1 (de) 2001-12-20
NO981984L (no) 1998-11-19
EP0904081B1 (en) 2001-11-14
HUS1100013I1 (hu) 2017-03-28
KR19990067603A (ko) 1999-08-25
EE03594B1 (et) 2002-02-15
NO981984D0 (no) 1998-04-30
SK62098A3 (en) 2000-04-10
JP2000513718A (ja) 2000-10-17
AU715572B2 (en) 2000-02-03
PL188309B1 (pl) 2005-01-31
CZ140198A3 (cs) 1999-04-14
BG102443A (en) 1999-06-30
CA2236691A1 (en) 1997-11-27
HU224025B1 (hu) 2005-05-30
IL124551A (en) 2001-08-26
HUP9901319A3 (en) 1999-11-29
DE69708284T2 (de) 2002-07-25
CN1093762C (zh) 2002-11-06
HUP9901319A2 (hu) 1999-08-30
UA61898C2 (en) 2003-12-15
NO2011015I1 (no) 2011-09-19
HK1017852A1 (en) 1999-12-03
IL124551A0 (en) 1998-12-06
KR100358373B1 (ko) 2003-02-11
CY2270B1 (en) 2003-07-04
ES2167745T3 (es) 2002-05-16
PT904081E (pt) 2002-04-29
CN1206347A (zh) 1999-01-27
DK0904081T3 (da) 2002-02-25
CY2011011I2 (el) 2016-12-14
CZ291284B6 (cs) 2003-01-15
NO2011015I2 (no) 2013-03-11
EP0904081A1 (en) 1999-03-31
ID16927A (id) 1997-11-20
TR199800923T2 (xx) 1999-09-21
PL327995A1 (en) 1999-01-04
CA2236691C (en) 2007-01-02

Similar Documents

Publication Publication Date Title
BR9706824B8 (pt) Suspensão aquosa de ésteres de ácido graxo de 9-hidróxi risperidona.
NO20002278D0 (no) Vandige suspensjoner av mikropartikkelformede 9- hydroksyrisperidonfettsyreestere
EE03426B1 (et) Risperidooni vesilahuselised ravimvormid
FI950910A (fi) Rasvahappojohdannaiset
MX9200450A (es) Suspensiones acuosas de acidos peroxicarboxilicos.
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
NO994595L (no) Salt av naftyridin-karboksylsyrederivat
DE59913680D1 (de) Fettsäurepartialester von Polyolen
PL335601A1 (en) Derivatives of 2-substituted benzoylcycloalkyl carboxylic acid
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
BR1100402A (pt) Derivados do ácido quinolona carboxìlico

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Z Decision to grant cancelled [chapter 9.1.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/08/2007, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061573/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132265-40.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:JANSSEN PHARMACEUTICA N.V, JOHNSON AND JOHNSON CONSUMER, NEUTROGENA CORPORATION, KEIKO OTSU LOUIS V. KIRCHHOFF.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061573/2013-23 13A VARA FEDERAL DO RIO DE JANEIRO PROCESSO : 0132265-40.2013.4.02.5101 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI REU: JANSSEN PHARMACEUTICA N.V. DECISAO: ANTECIPO OS EFEITOS DE TUTELA, A FIM DE DETERMINAR A IMEDIATA READEQUACAO DO PRAZO DE VIGENCIA DAS PATENTES PI9611184-4 E PI9706824-1 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, NOS TERMOS DO PARAGRAFO UNICO DO ART. 229 C/C O CAPUT DO ART.40 DA LPI. PI9611184-4 PRAZO DE VIGENCIA: 25.10.2016 PI9706824-1 PRAZO DE VIGENCIA:12.05.2017.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 1912 DE 22/04/2008, QUANTO AO PRAZO DE VALIDADE CONFORME DECISAO DO MM. JUIZ (A) DA 13A VARA FEDERAL DO RIO DE JANEIRO.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]
B19A Notification of judicial decision: notification of judicial decision